StreetInsider.com News Articles

Form 4 KalVista Pharmaceuticals For: Mar 06 Filed by: Palleiko Benjamin L

Tue, 10 Mar 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260310/26141088.html

Form 4 KalVista Pharmaceuticals For: Mar 06 Filed by: Palleiko Benjamin L

Tue, 10 Mar 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260310/26141088.html

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate of 6,750 shares of KalVista common stock on March 1, 2026 as inducements material to such employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date.

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 04 Mar 2026 07:00:00 -0400

One-fourth of the options vest on the one-year anniversary of the vesting commencement date

KalVista presents data showing high patient preference for oral HAE drug

Mon, 02 Mar 2026 07:01:13 -0400

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) presented clinical trial data at medical conferences showing patients prefer its oral hereditary angioedema treatment over injectable alternatives.

The data from the KONFIDENT-S open-label extension study showed that as of July 2025, patients treated 2,464 HAE attacks with sebetralstat, marketed as EKTERLY. Patient satisfaction remained at 83.1% across attacks rated as satisfied or better on a 7-point scale.

In the study, patients chose sebetralstat for 82.1% of attacks while using conventional injectable treatments for 16% of attacks. Only 1.9% of attacks went untreated. The use of injectable treatments decreased from 21% to 13% across the first five

KalVista presents data showing high patient preference for oral HAE drug

Mon, 02 Mar 2026 07:01:13 -0400

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) presented clinical trial data at medical conferences showing patients prefer its oral hereditary angioedema treatment over injectable alternatives.

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)